Black Rock Inc. T Scan Therapeutics, Inc. Call Options Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TCRX
# of Institutions
80Shares Held
37.7MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.86MShares$18.4 Million3.37% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$12.2 Million0.3% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$6.52 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$5.03 Million0.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA2.09MShares$4.88 Million3.67% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $44.3M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...